PF-05231023: Clinical Trials

4 trials of PF-05231023, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Terminated 1

Follow PF-05231023: new trials by email Literature Review of PF-05231023 trials Research Report on PF-05231023

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
Placebo, 100 mg PF-05231023 - Type 2 Diabetes Mellitus (T2DM)
Phase 1TerminatedPfizer42013-09-012014-09-17
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
Placebo, 25 mg PF-05231023, 50 mg PF-05231023 - Diabetes Melliuts, Type 2
Phase 1CompletedPfizer1072012-10-012015-02-16
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
PF-05231023, Placebo - Diabetes Mellitus, Type 2
Phase 1CompletedPfizer502011-07-012015-01-12
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
PF-05231023, Placebo - Diabetes Mellitus, Type 2
Phase 1CompletedPfizer842011-02-012016-11-18

Conditions studied

Diabetes Mellitus, Type 2 (4)  ·  Obesity (1)

Sponsors

Pfizer (4)

Countries

United States (4)

Results publications

PMID 28573777